- Markets
- Healthcare
- LASA
LASA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Lasa Supergenerics Approves Rights Issue To Raise Up To 490 Mln Rupees
Jan 28 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
TO ISSUE 2.5 MILLION CONVERTIBLE WARRANTS
APPROVES RIGHTS ISSUE TO RAISE UP TO 490 MILLION RUPEES
Source text: ID:nBSE4mm8Kj
Further company coverage: LASA.NS
(([email protected];;))
Jan 28 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
TO ISSUE 2.5 MILLION CONVERTIBLE WARRANTS
APPROVES RIGHTS ISSUE TO RAISE UP TO 490 MILLION RUPEES
Source text: ID:nBSE4mm8Kj
Further company coverage: LASA.NS
(([email protected];;))
Lasa Supergenerics To Consider Issue Of Warrants Convertible Into Equity Shares
Jan 22 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
BOARD TO CONSIDER ISSUE OF WARRANTS CONVERTIBLE INTO EQUITY SHARES
BOARD TO CONSIDER FUND RAISING THROUGH RIGHTS ISSUE
Source text: ID:nBSE2TtKfC
Further company coverage: LASA.NS
(([email protected];;))
Jan 22 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
BOARD TO CONSIDER ISSUE OF WARRANTS CONVERTIBLE INTO EQUITY SHARES
BOARD TO CONSIDER FUND RAISING THROUGH RIGHTS ISSUE
Source text: ID:nBSE2TtKfC
Further company coverage: LASA.NS
(([email protected];;))
India's Lasa Supergenerics gains after settlement of dues
** Shares of Lasa Supergenerics LASA.NS rise 4.7% to 29 rupees, their highest since Oct 1
** Stock last up 1.5%
** Active pharmaceutical ingredients drugs maker settles dispute for dues with Bank of Baroda
** Co says it has become debt-free
** Stock down 7% YTD
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Lasa Supergenerics LASA.NS rise 4.7% to 29 rupees, their highest since Oct 1
** Stock last up 1.5%
** Active pharmaceutical ingredients drugs maker settles dispute for dues with Bank of Baroda
** Co says it has become debt-free
** Stock down 7% YTD
(Reporting by Aleef Jahan in Bengaluru)
Lasa Supergenerics Says Dispute With Bank Of Baroda Settled
Oct 14 (Reuters) - Bank of Baroda [RIC:RIC:BOBXL.UL]:
LASA SUPERGENERICS - DISPUTE WITH BANK OF BARODA SETTLED
LASA SUPERGENERICS - ENTIRE SETTLED AMOUNT AGAINST CONCLUDED SETTLED SANCTION HAS BEEN PAID
LASA SUPERGENERICS - DISPUTE OF CO WITH BANK OF BARODA FOR ALLEGED ECB DUES
LASA SUPERGENERICS - RECEIVED NO DUES CERTIFICATE FROM BANK OF BARODA
Source text for Eikon: ID:nBSE1ht4mB
Further company coverage: BOBXL.UL
(([email protected];;))
Oct 14 (Reuters) - Bank of Baroda [RIC:RIC:BOBXL.UL]:
LASA SUPERGENERICS - DISPUTE WITH BANK OF BARODA SETTLED
LASA SUPERGENERICS - ENTIRE SETTLED AMOUNT AGAINST CONCLUDED SETTLED SANCTION HAS BEEN PAID
LASA SUPERGENERICS - DISPUTE OF CO WITH BANK OF BARODA FOR ALLEGED ECB DUES
LASA SUPERGENERICS - RECEIVED NO DUES CERTIFICATE FROM BANK OF BARODA
Source text for Eikon: ID:nBSE1ht4mB
Further company coverage: BOBXL.UL
(([email protected];;))
Lasa Supergenerics Got Patent For Processes For Preparation Of 5-Chloro-2-Nitroaniline
Sept 13 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
LASA SUPERGENERICS - GOT PATENT FOR PROCESSES FOR PREPARATION OF 5-CHLORO-2-NITROANILINE
Further company coverage: LASA.NS
(([email protected];))
Sept 13 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
LASA SUPERGENERICS - GOT PATENT FOR PROCESSES FOR PREPARATION OF 5-CHLORO-2-NITROANILINE
Further company coverage: LASA.NS
(([email protected];))
Lasa Supergenerics Names Varsha Pravin Joshi As CFO
July 25 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
NAMES VARSHA PRAVIN JOSHI AS CFO
Source text for Eikon: ID:nBSE1fZrY1
Further company coverage: LASA.NS
(([email protected];;))
July 25 (Reuters) - Lasa Supergenerics Ltd LASA.NS:
NAMES VARSHA PRAVIN JOSHI AS CFO
Source text for Eikon: ID:nBSE1fZrY1
Further company coverage: LASA.NS
(([email protected];;))
Events:
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Lasa Supergenerics do?
Lasa Supergenerics Limited, established in 2016 in Ratnagiri, Maharashtra, specializes in the manufacturing of API bulk drugs products.
Who are the competitors of Lasa Supergenerics?
Lasa Supergenerics major competitors are Mangalam Drugs&Org., Smruthi Organics, Tyche Inds, Bal Pharma, Everest Organics, SMS Lifesciences, Nectar Lifesciences. Market Cap of Lasa Supergenerics is ₹89 Crs. While the median market cap of its peers are ₹174 Crs.
Is Lasa Supergenerics financially stable compared to its competitors?
Lasa Supergenerics seems to be less financially stable compared to its competitors. Altman Z score of Lasa Supergenerics is 1.85 and is ranked 8 out of its 8 competitors.
Does Lasa Supergenerics pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Lasa Supergenerics latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Lasa Supergenerics allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Lasa Supergenerics balance sheet?
Balance sheet of Lasa Supergenerics is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Lasa Supergenerics improving?
Yes, profit is increasing. The profit of Lasa Supergenerics is -₹15.77 Crs for TTM, -₹21.73 Crs for Mar 2024 and -₹38.62 Crs for Mar 2023.
Is the debt of Lasa Supergenerics increasing or decreasing?
The debt of Lasa Supergenerics is decreasing. Latest debt of Lasa Supergenerics is ₹19.11 Crs as of Sep-24. This is less than Mar-24 when it was ₹19.18 Crs.
Is Lasa Supergenerics stock expensive?
Lasa Supergenerics is not expensive. Latest PE of Lasa Supergenerics is 0.0, while 3 year average PE is 3.63. Also latest EV/EBITDA of Lasa Supergenerics is 0.0 while 3yr average is 20.75.
Has the share price of Lasa Supergenerics grown faster than its competition?
Lasa Supergenerics has given lower returns compared to its competitors. Lasa Supergenerics has grown at ~-20.44% over the last 7yrs while peers have grown at a median rate of 4.94%
Is the promoter bullish about Lasa Supergenerics?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Lasa Supergenerics is 53.65% and last quarter promoter holding is 53.65%.
Are mutual funds buying/selling Lasa Supergenerics?
There is Insufficient data to gauge this.